share_log

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30

Benzinga Real-time News ·  Sep 27, 2022 06:41

Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $46 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment